2 Beaten-Down Stocks to Avoid Right Now

Teladoc Health's Q2 revenue fell 2% year over year to $631.9 million and it recorded a $0.19 per-share net loss, with BetterHelp facing heavy competition and continued profitability concerns. Sarepta Therapeutics has fallen 85% year to date after two Elevidys patients died from liver toxicity; Q2 revenue of $362.9 million was down 51.2% sequentially as Elevidys sales fell 67.5% to $121.7 million. While Sarepta resumed Elevidys shipments for ambulatory DMD patients and is cutting costs and refinancing debt, significant safety and regulatory uncertainty remains for both companies.

Analysis

TDOC's investability hinges less on member growth than on whether acquisition and marketing spend can be reduced without another decline in behavioral-health utilization. The likely competitive pressure is structural: lower-cost, employer-sponsored point solutions and AI-enabled therapy platforms can bid aggressively for the highest-value covered lives, leaving TDOC with weaker cohorts and adverse CAC/LTV economics. Over the next 1-3 quarters, any revenue stabilization without a meaningful improvement in adjusted EBITDA, BetterHelp retention, and cash conversion should be treated as a value-trap rally rather than a turnaround.

SRPT is now primarily a regulatory and pharmacovigilance-duration trade, not a conventional rare-disease growth story. A restricted addressable population materially reduces operating leverage because gene-therapy infrastructure, medical affairs, and patient-support costs are relatively fixed; expense cuts extend runway but do not restore the prior earnings-power narrative. The second-order read-through is negative for AAV gene-therapy peers with systemic delivery exposure—especially RGNX, SLDB and other early-stage neuromuscular programs—if regulators require broader liver-monitoring protocols, slower dosing cadence, or additional post-marketing evidence.

Consensus bearishness may be more actionable in SRPT than TDOC: an 85% drawdown can create sharp rallies if FDA language clarifies a workable risk-mitigation pathway for the remaining eligible population. But that upside is event-driven and vulnerable to asymmetric downside from another serious safety report, a label narrowing, or payer restrictions. TDOC lacks an equivalent discrete catalyst; its principal risk is slow multiple erosion as the market discounts recurring low growth and recurring restructuring/impairment risk.

For the next several days, avoid chasing either name lower on retail commentary alone. Over 1-3 months, SRPT's dosing trends, FDA correspondence, and payer behavior are the decisive catalysts; TDOC requires evidence that BetterHelp revenue and marketing intensity have bottomed. Over 6-18 months, the key divergence is whether SRPT can preserve a viable gene-therapy franchise versus whether TDOC can prove a durable, profitable integrated-care model.

Key Decisions for Investors

• Maintain TDOC as a short/watchlist underperformer rather than initiate on headline weakness. Add only on a relief rally if quarterly revenue remains flat-to-down while adjusted EBITDA or free-cash-flow guidance fails to improve; cover if BetterHelp growth reaccelerates for two consecutive quarters alongside lower marketing spend as a percentage of revenue.
• Treat SRPT as event-risk only: avoid unhedged long exposure ahead of FDA safety or label updates. For investors requiring exposure, use a defined-risk call spread 3-6 months out rather than common stock; the thesis requires verifiable resumed dosing and a stable safety interval, while another liver-related serious adverse event invalidates the bullish setup.
• Consider a basket hedge in AAV gene therapy—short a diversified high-beta gene-therapy proxy or selected systemic-AAV peers against any SRPT tactical long—until the regulatory response establishes whether monitoring and eligibility changes are company-specific or class-wide.
• Set an SRPT alert for sequential Elevidys demand stabilization and any explicit payer coverage changes. A sustained recovery in treated-patient volume without incremental restrictions would support a tactical rebound; a further material sequential decline despite resumed shipping argues for reduced revenue estimates and renewed downside.